ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

Key Highlights

• ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology company, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026.
• Mr. Knight brings over 30 years of leadership experience in the biopharmaceutical industry, with a track record of advancing oncology programs from early development through commercialization.
• The company is entering a critical phase with multiple anticipated catalysts in the next 12 to 18 months, especially in its evorpacept and ALX2004 clinical programs.
• Mr. Knight’s background includes key roles at Crinetics Pharmaceuticals, Poseida Therapeutics, Halozyme Therapeutics, Amgen, Onyx Pharmaceuticals, and Genentech—all notable names in the industry.
• ALX Oncology’s lead candidate, evorpacept, is positioned as a potential cornerstone therapy in immuno-oncology and is being tested in multiple ongoing clinical trials.
• The company’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate currently in a Phase 1 trial.

Details and Potential Impact for Investors

The appointment of Jeff Knight as Chief Development and Operating Officer represents a significant strengthening of ALX Oncology’s leadership team at a pivotal moment in the company’s development. Knight’s extensive experience is expected to be instrumental as ALX prepares for several important milestones over the next 12 to 18 months, including the advancement of its flagship programs—evorpacept and ALX2004—through late-stage clinical development and potential commercialization.

According to CEO Jason Lettmann, Knight’s expertise in clinical development, regulatory affairs, and operational excellence directly aligns with ALX Oncology’s near-term operational and strategic needs. Notably, Knight’s prior leadership roles with companies such as Crinetics Pharmaceuticals, Poseida Therapeutics, Halozyme Therapeutics, Amgen, Onyx Pharmaceuticals, and Genentech highlight his capability to navigate complex late-stage development and commercialization processes, particularly in oncology.

For shareholders, the announcement underscores several price-sensitive factors:

• Leadership Strengthening: The addition of Knight, with his proven track record, may be viewed positively by the market as a move to ensure robust execution of key clinical and corporate milestones.
• Upcoming Catalysts: The company forecasts “several important catalysts” within the next 12 to 18 months for its clinical programs, which could include pivotal data readouts, regulatory submissions, or partnership opportunities. Such events are typically significant share price drivers.
• Pipeline Progress: Both evorpacept and ALX2004 are at critical junctures. Evorpacept is being evaluated in multiple cancer indications, while ALX2004 is undergoing a Phase 1 dose-escalation trial in patients with EGFR-expressing solid tumors.

Mr. Knight holds a Master of Public Health in Biostatistics and Epidemiology and a Bachelor of Arts in Psychology from the University of Oklahoma, as well as a Bachelor of Science in Nursing from the University of Kansas. His credentials further reinforce the depth of expertise being added to ALX Oncology’s executive ranks.

About ALX Oncology

ALX Oncology is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. The lead therapeutic candidate, evorpacept, has demonstrated potential as a foundational therapy in immuno-oncology, and ALX2004, a novel EGFR-targeted antibody-drug conjugate, is being tested in early clinical trials. More information is available at www.alxoncology.com and on LinkedIn at ALX Oncology.

Cautionary Note on Forward-Looking Statements

This article includes forward-looking statements based on management’s current expectations regarding future operations, clinical program progress, regulatory outlook, and potential catalysts. Actual results may differ due to risks and uncertainties, including those identified in ALX Oncology’s filings with the SEC. Investors are encouraged to review these filings for a comprehensive understanding of the risks involved.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions.

View ALX ONCOLOGY HOLDINGS INC Historical chart here